

## iTrack™ Advance First Surgeries and Sales in USA

- **First surgeries with iTrack™ Advance completed in the U.S.A**
- **First sales in the U.S.A. recorded during April.**

Nova Eye Medical Limited (ASX: **EYE**) (**Nova Eye** or the **Company**), is pleased to announce that following clearance by the U.S. Food and Drug Administration (FDA) on 31 March 2023, it has commenced the launch of *iTrack™ Advance* in the USA to treat glaucoma.

### Key activities are as follows:

- Successfully completed the first surgery in the USA on 11 April 2023. Since then, first surgeries have since been conducted by several of our key opinion leaders.
- Initial sales targeting has focussed on existing accounts and the first sales of *iTrack™ Advance* were recorded in April. Feedback on device performance has been very positive.
- Following initial sales to existing customers, the sales team will continue to introduce *iTrack™ Advance* to the surgeons experienced with *iTrack™*. These surgeons are familiar with the surgical technique and the efficacy of our original *iTrack™* catheter.
- First additional sales representatives have been recruited and this recruitment process is continuing.

### Mr Tom Spurling, Managing Director Nova Eye Medical commented:

*“We are pleased with the support provided by our existing customers as we commence the commercial roll out. We look forward to the acceleration of sales as we generate new customer interest.”*

For more information about *iTrack™ Advance*, including important safety information, visit: [itrack-advance.com](http://itrack-advance.com)

For additional information about Nova Eye Medical and its technologies, visit: [nova-eye.com](http://nova-eye.com)

## Authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited

– ENDS –

### **Tom Spurling**

Managing Director

+61 417 818 658

[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

### **Kate Hunt**

Chief Commercial Officer

+61 404 080 679

[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

### **Mark Flynn**

Investor Relations

+61 416 068 733

[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

---

## **ABOUT NOVA EYE MEDICAL LIMITED**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long term IOP control in cases of severe glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

---

## **ABOUT THE iTRACK™ PORTFOLIO**

For additional information about *iTrack™ Advance*, including safety information, please visit: [itrack-advance.com](http://itrack-advance.com)